GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study

OBJECTIVE: To assess the efficacy and safety of lenzilumab in patients with severe coronavirus disease 2019 (COVID-19) pneumonia. METHODS: Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an eme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mayo Clin Proc
Main Authors: Temesgen, Zelalem, Assi, Mariam, Shweta, F.N.U., Vergidis, Paschalis, Rizza, Stacey A., Bauer, Philippe R., Pickering, Brian W., Razonable, Raymund R., Libertin, Claudia R., Burger, Charles D., Orenstein, Robert, Vargas, Hugo E., Palraj, Raj, Dababneh, Ala S., Chappell, Gabrielle, Chappell, Dale, Ahmed, Omar, Sakemura, Reona, Durrant, Cameron, Kenderian, Saad S., Badley, Andrew D.
Formato: Artigo
Idioma:Inglês
Publicado em: Mayo Foundation for Medical Education and Research 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7470718/
https://ncbi.nlm.nih.gov/pubmed/33153629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mayocp.2020.08.038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados